radafaxine
Small moleculeexperimental
Radafaxine (developmental code GW-353,162; also known as (2S,3S)-hydroxybupropion or (S,S)-hydroxybupropion) is a norepinephrine–dopamine reuptake inhibitor (NDRI) which was under development by GlaxoSmithKline in the 2000s for a variety of different indications but was never marketed. These uses included treatment of restless legs syndrome, major depressive disorder, bipolar disorder, neuropathic pain, fibromyalgia, and obesity. Regulatory filing was planned for 2007, but development was discontinued in 2006 due to "poor test results". — Wikipedia
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2003 (NCT00057226)
Timeline
2000s
- Jan 1, 2003
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Norepinephrine transporterINHIBITOR
SLC6A2 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1NC(C)(C)CO[C@@]1(O)c1cccc(Cl)c1- Mol. weight
- 255.74 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRadafaxine ↗
- ChEMBLCHEMBL1172928 ↗
Also known as
- 2-morpholinol, 2-(3-chlorophenyl)-3,5,5-trimethyl-, (2s,3s)-
- radafaxine
- radafaxine
- radafaxine
- radafaxine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00057213 | Phase 2 | Mar 1, 2003 | GlaxoSmithKline |
| NCT00057226 | Phase 2 | Mar 1, 2003 | GlaxoSmithKline |
| NCT00057239 | Phase 2 | Mar 1, 2003 | GlaxoSmithKline |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 3 | 3 | 1 | 2003 |
1 organizations
Page 1 / 1